ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters

OMICS A Journal of Integrative Biology

Volumn 15, Issue 5, 2011, Pages 305-312

  Dell'Orso, Stefania ^a   Fontemaggi, Giulia ^a,b   Stambolsky, Perry ^c   Goeman, Frauke ^a   Voellenkle, Christine ^d   Levrero, Massimo ^e   Strano, Sabrina ^a   Rotter, Varda ^c   Oren, Moshe ^c   Blandino, Giovanni ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d Research Laboratories Molecular Cardiology   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; PROTEIN P300; PROTEIN P53; TRANSCRIPTION FACTOR RELA;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL CULTURE; CHROMATIN IMMUNOPRECIPITATION; HUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING;

AMINO ACID SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; DNA-BINDING PROTEINS; HUMANS; MUTANT PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; P300-CBP TRANSCRIPTION FACTORS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79956139237     PISSN: 15362310     EISSN: 15362310     Source Type: Journal    
DOI: 10.1089/omi.2010.0084     Document Type: Article

References (18)

1. Brosh, R., and Rotter V. (2009). When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9, 701-713.
2. Brummelkamp, T.R., Bernards, R., & Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550-553. (Pubitemid 34408678)
3. Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., et al. (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10, 191-202. (Pubitemid 44311070)
4. Fontemaggi, G., Gurtner, A., Strano, S., Higashi, Y., Sacchi, A., Piaggio, G., et al. (2001). The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 21, 8461-8470. (Pubitemid 33108605)
5. Fontemaggi, G., Dell'Orso, S., Trisciuoglio, D., Shay, T., Melucci, E., Fazi, F., et al. (2009). The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16, 1086-1093.
6. Fontemaggi, G., Dell'Orso, S., Muti, P., Blandino, G., and Strano, S. (2010). Id2 gene is a transcriptional target of the protein complex mutant p53/E2F1. Cell Cycle 9.
7. Langerød, A., Zhao, H., Borgan, Ø., Nesland, J.M., Bukholm, I.R., Ikdahl, T., et al. (2007). TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 9, R30.
8. Mü ller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li- Weber, M., et al. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188, 2033-2045. (Pubitemid 28562520)
9. Oberley, M.J., Tsao, J., Yau, P., and Farnham, P.J. (2004). Highthroughput screening of chromatin immunoprecipitates using CpG-island microarrays. Methods Enzymol 376, 315-334. (Pubitemid 38200188)
10. Oren, M., and Rotter, V. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2, a001107.
11. Owen-Schaub, L.B., Zhang, W., Cusack, J.C., Angelo, L.S., Santee, S.M., Fujiwara, T., et al. (1995). Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol 15, 3032-3040.
12. Petitjean, A., Achatz, M.I., Borresen-Dale, A.L., Hainaut, P., and Olivier, M. (2007). TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157-2165. (Pubitemid 46536647)
13. Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., et al. (2010). Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17, 273-285.
14. Strano, S., Dell'orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., Blandino G. (2007). Mutant p53: an oncogenic transcription factor. Oncogene 26, 2212-2219. (Pubitemid 46536646)
15. Wang, Y., Kringen, P., Kristensen, G.B., Holm, R., Baekelandt, M.M., Olivier, M., et al. (2004a). Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival inpatients with advanced ova ian carcinoma. Hum Mutat 24, 21-34. (Pubitemid 38859221)
16. Wang, Y., Helland, A., Holm, R., Skomedal, H., Abeler, V.M., Danielsen, H.E., et al. (2004b). TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. Br J Cancer 90, 678-685. (Pubitemid 38297210)
17. Weisz, L., Damalas, A., Liontos, M., Karakaidos, P., Fontemaggi, G., Maor-Aloni, R., et al. (2007). Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67, 2396-2401. (Pubitemid 46548921)
18. Zalcenstein, A., Stambolsky, P., Weisz, L., Mü ller, M., Wallach, D., Goncharov, T.M., et al. (2003). Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumorassociated p53 mutants. Oncogene 22, 5667-5676. (Pubitemid 37102703)